NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Last trade$19.44
Day change-$0.02 (-0.10%)
Day range$18.93 – $20.98
Volume723,982
Market cap$2.33B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.33B
Price / earnings
—
Price / book
3.7×
Price / sales
89.98×
EV / sales
73.67×
EV / EBITDA
-8.19×
Profitability
Earnings per share
-$1.71
Return on assets
-29.78%
Return on equity
-32.48%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
11.76×
Quick ratio
11.76×
Cash ratio
7.4×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$150.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NAMS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$19.16M
$3.7M
$3.04M
$32K
$348K
$19.15M
$2.98M
$12.77M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$19.16M
$3.7M
$3.04M
$32K
$348K
$19.15M
$2.98M
$12.77M
Selling, general and administrative
$24M
$26.89M
$23.45M
$27.42M
$24.52M
$27.26M
$27.15M
$21.11M
Research and development
$39.36M
$41.67M
$38.01M
$38.59M
$30.97M
$27.52M
$44.75M
$34.9M
Total operating expenses
$63.35M
$68.57M
$61.46M
$66.01M
$55.49M
$54.78M
$71.9M
$56M
Operating income
-$44.19M
-$64.86M
-$58.42M
-$65.98M
-$55.14M
-$35.64M
-$68.93M
-$43.23M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$16.18M
-$64.14M
-$48.44M
-$74.92M
-$72.01M
-$17.36M
-$39.53M
-$92.18M
Income taxes
$1.21M
$0
$0
$0
$0
$0
$0
$0
Net income
-$17.39M
-$64.14M
-$48.44M
-$74.92M
-$72.01M
-$17.36M
-$39.53M
-$92.18M
Net income attributable to common shareholders
-$17.39M
-$64.14M
-$48.44M
-$74.92M
-$72.01M
-$17.36M
-$39.53M
-$92.18M
EBITDA
-$44.12M
-$64.81M
-$58.36M
-$65.92M
-$55.08M
-$35.59M
-$68.87M
-$43.18M
Basic earnings per share
-$0.14
-$0.52
-$0.40
-$0.62
-$0.61
-$0.15
-$0.34
-$0.93
Diluted earnings per share
-$0.14
-$0.52
-$0.40
-$0.62
-$0.61
-$0.15
-$0.34
-$0.93
Recent news
Company coverage with links to the original publishers.
NewAmsterdam Pharma announced it will present multiple data presentations on obicetrapib, its novel oral CETP inhibitor for cholesterol management, at the NLA 2026 Scientific Sessions in Chicago on June 11-14, 2026. The presentations will cover clinical trial safety assessments, efficacy data from Phase 3 trials (BROADWAY and BROOKLYN), and real-world evidence on statin intolerance. The company has also granted European commercialization rights to the Menarini Group.
NewAmsterdam Pharma announced that company management will participate in investor conferences including the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The company is developing obicetrapib, an oral CETP inhibitor, for LDL-C lowering in cardiovascular disease patients, with regulatory decisions from EMA, UK, and Switzerland expected in the second half of 2026.
NewAmsterdam Pharma's Compensation Committee approved inducement grants of 50,400 share options and 15,400 restricted stock units to five new non-executive employees. The options have an exercise price of $28.43 per share with four-year vesting, while RSUs vest over three years. These grants were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma's Compensation Committee approved inducement grants of 15,000 share options and 3,200 restricted stock units to two non-executive new hires. The options have an exercise price of $32.81 per share with four-year vesting, while RSUs vest over three years. Both grants were made under the 2024 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
NewAmsterdam Pharma announced that its CFO Ian Somaiya and EVP of Investor Relations Matthew Philippe will participate in a virtual fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026. The company is a late-stage biopharmaceutical firm developing obicetrapib, an oral CETP inhibitor for LDL-C lowering in cardiovascular disease patients, with EMA approval decisions expected in H2 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.